For municipalities looking to stoke an innovation ecosystem, an anchor industry can provide the needed spark. One of the best anchor-industry bets around is biosciences.
The research team’s findings could be used to eventually help verify the effectiveness of any new vaccine for the disease.
Missoula-based Inimmune Corporation receives funds for cutting edge infectious disease research and novel immunotherapeutic treatments
The six-month grant will fund early discovery research efforts at Inimmune to develop new immunotherapy drugs for treating and preventing upper respiratory tract infections, including influenza.
We provide a complete end-to-end solution for clinical labs and hospitals to analyze Next-Generation Sequencing data.
The bioscience’s need for a stable and supportive public policy framework is vital to industry firms large and small.
The new law earmarks $6.3 billion for biomedical research and other programs, and clears the way for the Food and Drug Administration to require less data for drug approvals if the drug is already approved for other conditions.
Kapperud said BioScience isn’t conducting any weird experiments involving Frankenstein.
"As Montana’s economy grows and diversifies, getting research breakthroughs to market quickly propels new innovations, new businesses and more technical, high-paying jobs for Montana," Governor Bullock said.
Scientists have tried to tap internet donors, too, with mixed success. Scientists raising funds for the world’s first imaging study of the brain on LSD raised more than $65,000 earlier this year, more than twice their goal.
Takeda, based in Osaka, Japan, bought the Bozeman company LigoCyte Pharmaceuticals in 2012. It said last year it was closing the Bozeman site and others as part of a two-year effort to consolidate its vaccine business in the Boston area.